Not yet....entered commercialisation during COVID-19 so slower than expected but make no mistake RAP is starting to finally realise the massive revenue potential, there is no technology limitation and ResAppDx offer a big point of difference to what is currently used for respiratory disease diagnosis so it's only a matter of when and not if.